In vitro and in vivo characterization of temoporfin-loaded PEGylated PLGA nanoparticles for use in photodynamic therapy.
暂无分享,去创建一个
Janko Kos | Elena Reddi | J. Kos | E. Reddi | L. Celotti | C. Compagnin | P. Kocbek | E. Papini | J. Woodhams | A. MacRobert | W. Helfrich | Wijnand Helfrich | Dietrich Scheglmann | F. Moret | Petra Kocbek | Melissa J Bovis | Lucia Celotti | Emanuele Papini | Chiara Compagnin | Matija Rojnik | M. Bovis | D. Scheglmann | Marco J Verkaik | Matija Rojnik | Francesca Moret | Josephine H Woodhams | Alexander J Macrobert
[1] M. C. Berenbaum,et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. , 1991, British journal of cancer.
[2] R. Senior,et al. 12-o-Tetradecanoyl-phorbol-13-acetate-differentiated U937 cells express a macrophage-like profile of neutral proteinases. High levels of secreted collagenase and collagenase inhibitor accompany low levels of intracellular elastase and cathepsin G. , 1986, The Journal of clinical investigation.
[3] J. Kos,et al. Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. , 2004, Experimental cell research.
[4] T. Kiesslich,et al. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. , 2010, Journal of photochemistry and photobiology. B, Biology.
[5] P. McCarron,et al. Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms , 2008 .
[6] Jayanth Panyam,et al. Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] J. Kos,et al. Proinflammatory effects of bare and PEGylated ORMOSIL-, PLGA- and SUV-NPs on monocytes and PMNs and their modulation by f-MLP. , 2011, Nanomedicine.
[8] F. Guillemin,et al. Correlation between in vivo pharmacokinetics, intratumoral distribution and photodynamic efficiency of liposomal mTHPC. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[9] L. Bezdetnaya,et al. Spectroscopic and Biological Testing of Photobleaching of Porphyrins in Solutions * , 1996, Photochemistry and photobiology.
[10] D. Vernon,et al. Identification and Partial Characterization of an Unusual Distribution of the Photosensitizer meta‐Tetrahydroxyphenyl Chlorin (Temoporfin) in Human Plasma , 1999, Photochemistry and photobiology.
[11] K. Avgoustakis,et al. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. , 2005, International journal of pharmaceutics.
[12] J. Kos,et al. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours , 2005, Expert opinion on biological therapy.
[13] A. Moor,et al. Signaling pathways in cell death and survival after photodynamic therapy. , 2000, Journal of photochemistry and photobiology. B, Biology.
[14] R. Gurny,et al. Toward the understanding of the photodynamic activity of m-THPP encapsulated in PLGA nanoparticles: correlation between nanoparticle properties and in vivo activity , 2009, Journal of drug targeting.
[15] Robert Gurny,et al. Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[16] N. Oleinick,et al. The photobiology of photodynamic therapy: cellular targets and mechanisms. , 1998, Radiation research.
[17] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[18] Stanley B. Brown,et al. The high photoactivity of m-THPC in photodynamic therapy. Unusually strong retention of m-THPC by RIF-1 cells in culture. , 1999 .
[19] K. Avgoustakis,et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. , 2003, International journal of pharmaceutics.
[20] G. Miotto,et al. The cellular uptake of meta-tetra(hydroxyphenyl)chlorin entrapped in organically modified silica nanoparticles is mediated by serum proteins , 2009, Nanotechnology.
[21] C. M. Agrawal,et al. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. , 1996, Biomaterials.
[22] Kohei Tahara,et al. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. , 2009, International journal of pharmaceutics.
[23] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[24] G. Dolivet,et al. Temoporfin‐mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study , 2010, Head & neck.
[25] Stephen G Bown,et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. , 2002, The Journal of urology.
[26] Matthias G. Wacker,et al. Photosensitizer loaded HSA nanoparticles II: in vitro investigations. , 2011, International journal of pharmaceutics.
[27] V. Labhasetwar,et al. Biodegradable nanoparticles for cytosolic delivery of therapeutics. , 2007, Advanced drug delivery reviews.
[28] Zhiyuan Hu,et al. Meso-tetra (carboxyphenyl) porphyrin (TCPP) nanoparticles were internalized by SW480 cells by a clathrin-mediated endocytosis pathway to induce high photocytotoxicity. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[29] I. Tan,et al. mTHPC‐mediated photodynamic therapy for early oral squamous cell carcinoma , 2004, International journal of cancer.
[30] R. Gurny,et al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. , 2004, International journal of pharmaceutics.
[31] Peter H Lin,et al. Current advances in research and clinical applications of PLGA-based nanotechnology , 2009, Expert review of molecular diagnostics.
[32] P. Morlière,et al. Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan® localisation in cultured tumour cells , 2003, British Journal of Cancer.
[33] François Guillemin,et al. Investigation of Foscan interactions with plasma proteins. , 2005, Biochimica et biophysica acta.
[34] Yong Zhang,et al. Nanoparticles in photodynamic therapy: an emerging paradigm. , 2008, Advanced drug delivery reviews.
[35] R. Gurny,et al. Encapsulation of p-THPP into Nanoparticles: Cellular Uptake, Subcellular Localization and Effect of Serum on Photodynamic Activity¶ , 2003 .
[36] G. Jori,et al. Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. , 1996, Journal of photochemistry and photobiology. B, Biology.
[37] R. Gurny,et al. In vitro and in vivo activities of verteporfin-loaded nanoparticles. , 2005, Journal of controlled release : official journal of the Controlled Release Society.